The Number of Positive Tumor Marker Status Is Beneficial for the Selection of Therapeutic Modalities in Patients with Hepatocellular Carcinoma

Toru Beppu1,2, Shigeki Nakagawa2, Hidetoshi Nitta2, Hirohisa Okabe2, Takayoshi Kaida2, Katsunori Inai2, Hiromitsu Hayashi2, Yuki Koga1,2, Kunitaka Kuramoto1,2, Daisuke Hashimoto2, Yo-ichi Yamashita2, Akira Chikamoto2, Takatoshi Ishiko2 and Hideo Baba2

1Department of Surgery, Yamaga City Medical Center, Kumamoto, Japan; 2Department of Gastroenterological Surgery, Graduate School of Life Sciences, Kumamoto University, Kumamoto, Japan

Abstract

Hepatic resection (HR) and radiofrequency ablation (RFA) are popular local therapies for early-stage hepatocellular carcinoma (HCC). Alpha-fetoprotein, \textit{Lens culinaris} agglutinin-reactive fraction of alpha-fetoprotein, and des-\textit{\gamma}-carboxy prothrombin are well-known and useful tumor markers for HCC. The positive number status of these tumor markers has recently been demonstrated as beneficial for predicting outcome for HCC patients treated with local therapy. Although the normal ranges reported have differed by institution, the positivity of tumor markers is consistent and can easily be assessed. Kumamoto and Wakayama's group clearly demonstrated the following: 1) Regardless of the degree of tumor stage, a triple-positive tumor marker profile can predict poor outcome in HCC patients undergoing HR; 2) For RFA alone, HCC patients with double- and triple-positive status, having less than three lesions and lesions $\leq 3$ cm in diameter show comparably insufficient outcomes; 3) For HCC patients with lesions $\leq 5$ cm in Child–Pugh grade A, HR is preferred over RFA; 4) Microvascular invasion rates increased even in the double-positive patients, while poorly differentiated HCC was frequently observed only in the triple-positive patients; and 5) RFA with chemoembolization, anatomical liver ressection, and postoperative adjuvant chemoembolization or hepatic arterial chemotherapy might improve the outcome for patients with highly malignant HCC with multiple positive tumor markers. However, the impacts of these therapies still need to be evaluated in prospective comparative studies.

Citation of this article: Beppu T, Nakagawa S, Nitta H, Okabe H, Kaida T, Imai K, et al. The number of positive tumor marker status is beneficial for the selection of therapeutic modalities in patients with hepatocellular carcinoma. J Clin Transl Hepatol 2017;5(2):165–168. doi: 10.14218/JCTH.2016.00055.

Introduction

Hepatic resection (HR) and radiofrequency ablation (RFA) are common and curative treatments for early-stage hepatocellular carcinoma (HCC). Numerous papers have been published about various tumor markers as indicators of postoperative outcomes. Among them, alpha-fetoprotein (AFP), \textit{Lens culinaris} agglutinin-reactive fraction of alpha-fetoprotein (AFP-L3), and des-\textit{\gamma}-carboxy prothrombin (DCP) are well-known useful tumor markers. Various cutoff levels of these tumor markers have been used; however, the normal limits reported from the various institutes are often different. Thus, optimal cutoff levels cannot be universally applied in studies. On the other hand, the determination of negativity or positivity for tumor markers is quite easy and can be performed regardless of the institutional cutoff values. Recently, the status of three positive tumor markers (AFP, AFP-L3 and DCP) was established as a beneficial prognostic factor for HCC patients treated with HR or RFA.

Histological HCC, characterized by features including microvascular invasion (MI) and tumor differentiation (TD), is a great prognostic factor for HR and RFA. Highly malignant tumors have worse postoperative outcomes; however, the curability of the two treatment modalities might be different according to the grade of tumor malignancy. It has been recently reported that the expression status of positive markers can predict histological tumor malignancy.

In this review, we have summarized the correlation between the expression number of positive markers and the therapeutic effects of local therapy in HCC patients.

Number of positive tumor markers and prognosis in HCC patients undergoing HR

Two studies have reported on the expression number of positive tumor markers and prognosis in HCC patients treated with HR (Table 1). The tumor markers studied were AFP, AFP-L3, and DCP. Kiriyama and colleagues

Keywords: Triple-positive tumor markers; Double-positive tumor markers; Hepatocellular carcinoma; Hepatic resection; Radiofrequency ablation; Alpha-fetoprotein; Des-\textit{\gamma}-carboxy prothrombin; \textit{Lens culinaris} agglutinin-reactive fraction of alpha-fetoprotein.

Abbreviations: AFP, alpha-fetoprotein; AFP-L3, \textit{Lens culinaris} agglutinin-reactive fraction of alpha-fetoprotein; DCP, des-\textit{\gamma}-carboxy prothrombin; DSS, disease-specific survival; HCC, hepatocellular carcinoma; HR, hepatic resection; HZR, hazard ratio; MI, microvascular invasion; OS, overall survival; RFA, radiofrequency ablation; RFS, recurrence-free survival; TD, tumor differentiation.

Received: 26 October 2016; Revised: 11 April 2017; Accepted: 13 April 2017

*Correspondence to: Toru Beppu, Department of Surgery, Yamaga City Medical Center, 511, Yamaga, Kumamoto 861-0593, Japan. Tel: +81-968-44-2185, Fax: +81-968-44-2420, E-mail: tbeppu@kumamoto-u.ac.jp

Journal of Clinical and Translational Hepatology 2017 vol. 5 | 165–168
evaluated 185 resected HCC patients, known as the Wakayama cohort. Our group also evaluated 199 resected HCC patients that met the Milan criteria, the Kumamoto cohort which included a larger number of early-stage HCC patients (in comparison with the Wakayama cohort). In the Kumamoto cohort, the number of positive tumor markers was significantly associated with larger tumor size (>3 cm) and multiple tumors. Based on a qualitative assessment of these three tumor markers, there were 29.6% and 13.0% negative, 37.2% and 40.5% single positive, 19.1% and 25.4% double positive, and 14.1% and 21.1% triple positive, respectively in the Kumamoto and Wakayama cohorts.

In the Kumamoto cohort, the 5-year recurrence-free survival (RFS) rate was significantly worse for the triple positive group compared to the non-triple positive group (17.1% vs. 29.5%, \( p = 0.038 \)). The 5-year overall survival (OS) rates were 61.4% and 80.2% for the triple positive and non-triple multiple tumors (HZR, 2.53; 95% CI, 1.73–2.00; 95% confidence interval (CI), 1.03–2.97). Notably, for poor OS, the independent risk factors were indocyanine green 15-min retention rate >12.6% (HZR, 1.65; \( p = 0.015 \)), non-initial treatment (HZR, 1.87; \( p = 0.005 \)), and triple positive tumor markers status (HZR, 1.68; \( p = 0.038 \)); and, for poor OS, the independent predictive factors were indocyanine green 15-min retention rate >12.6% (HZR, 2.46; \( p = 0.0146 \)), maximum tumor diameter >3 cm (HZR, 2.71; \( p = 0.004 \)), and triple positive tumor markers status (HZR, 2.57; \( p = 0.020 \)).

In the Wakayama cohort, the 2-year RFS rates were 19.4%, 38.2%, 55.5%, and 50.7% in the triple positive, double positive, single positive, and triple negative groups, respectively. The frequency of triple positive patients was 35.9%, 54.7%, 82.9%, and 62.8% in the same groups. Multivariate analysis demonstrated that independent risk factors for poor RFS included Child–Pugh class B [HZR, 2.00; 95% confidence interval (CI), 1.03–3.87], presence of multiple tumors (HZR, 2.53; 95% CI, 1.73–3.71), and triple positive markers status (HZR, 1.78; 95% CI, 1.10–2.86); and, for poor DSS, the independent risk factors were presence of multiple tumors (HZR, 2.38; 95% CI, 1.31–4.33) and triple positive markers status (HZR, 2.41; 95% CI, 1.20–4.83).

Thus, regardless of the degree of tumor stage, a triple positive tumor marker profile was an independent predictive factor for both recurrence and long-term survival in HCC patients who underwent HR.

### Number of positive tumor markers and prognosis in HCC patients undergoing RFA

We recently reported the utility of determining the number of positive tumor markers for HCC patients treated with RFA (Table 1). A total of 160 patients with less than three lesions and with lesions no more than 3 cm in diameter were selected and treated with percutaneous, endoscopic or open RFA. The pre-treatment positive rates of these markers were 31.9%, 43.1%, 19.4%, and 5.6% in the negative, single positive, double positive, and triple positive tumor marker groups, respectively. The frequency of triple positive patients was less in the RFA group than in the HR group. Interestingly, in the RFA group, the double and positive tumor marker HCCs provided similarly insufficient outcomes. The 3-year RFS rates were 30%, 19%, 16%, and 11% (\( p = 0.02 \)) and the OS rates were 94%, 88%, 67%, and 37% (\( p < 0.001 \)) in the negative, single, double, and triple positive groups, respectively. The 2-year local recurrence rates at the adjacent area of initial ablated lesion were 6.5%, 0%, 41.2%, and 61.9%, respectively in these groups (\( p < 0.001 \)). By multivariate analysis, a double or triple positive tumor marker status was an independent risk factor for poor OS (HZR, 4.21; 95% CI, 1.89–9.37; \( p < 0.001 \)) and local recurrence (HZR, 5.48; 95% CI, 2.44–12.33; \( p < 0.001 \)).

### Selection of HR or RFA for HCC patients by assessment of the number of positive tumor markers

The Wakayama group recently reported the utility of positive conditions of tumor markers for treatment selection of patients with HCC (Table 1). A total of 296 patients with solitary HCC of ≤5 cm and presenting Child–Pugh grade A (136 HR and 160 RFA) were analyzed. Actually, in the HR group, the frequency of patients undergoing anatomical resection was increased among patients with positive status for three
Beppu T. et al.: Positive tumor marker number status and HCC tumor markers, while in the RFA group, the frequency of patients treated with RFA following chemoembolization was increased among patients with positive status for three tumor markers. The 5-year OS rates of HR and RFA were similar, 70.1% and 69.8%, respectively ($p = 0.14$). Conversely, when we analyzed their outcome according to the positive number of three tumor markers, the 5-year OS rates were 60.6%, 78.2%, 54.2%, and 75.9% in the HR group, whereas the rates were 83.3%, 75.7%, 62.2%, and 47.6% in the RFA group, respectively, in patients with negative, single positive, double positive, and triple positive tumor markers. The $p$-values were different between patients treated with HR and RFA: 0.45 in negative, 0.10 in single positive, 0.77 in double positive, and $<0.01$ in triple positive. By multivariate analysis, RFA application was an independent poor prognostic factor for a tumor size of $\leq 5$ cm in Child–Pugh grade A.

**Number of positive tumor markers and histological malignancy of HCC**

Three studies have reported on the expression number of positive tumor markers and histological HCC malignancy. We presented the data from patients with HCC who met the Milan criteria in the Kumamoto cohort and from patients with solitary HCC $\leq 5$ cm in diameter in the Wakayama cohort. Positive data from the Kumamoto and Wakayama cohorts are depicted in Fig. 1. MI rates rose significantly in a stepwise manner according to the increased number of positive tumor markers expressed. For the Kumamoto and Wakayama cohorts, respectively, these were 18.6% and 16.7% in the negative group, 27.0% and 29.3% in the single positive group, 39.5% and 46.8% in the double positive group, and 53.6% and 56.4% in the triple positive group.

The percentage of poor TD was significantly increased only in the triple positive group in the Kumamoto cohort (negative, 17.0%; single positive, 17.6%; double positive, 13.2%; triple positive, 46.4%). Similarly, tumors representing the Edmondson–Steiner classification grades III or IV were significantly different among the four groups in the Wakayama cohort (negative, 12.5%; single positive, 13.3%; double positive, 25.5%; triple positive, 35.9%). The rate of invasive growth showed a stepwise increase among the four groups in the Kumamoto cohort (negative, 0%; single positive, 8.2%; double positive, 10.5%; triple-positive, 17.9%).

**Treatment strategy in consideration of the positive tumor marker number profile**

The positive tumor marker number profile can clearly estimate recurrence and prognosis in HCC patients who have undergone local therapy, like HR and RFA. Preoperative assessment for higher recurrence risk allows for planning of an appropriate treatment strategy. According to the histological examination, MI rates increased even in the double positive patients. Both poor differentiation and MI were frequently observed in the triple positive patients. These characteristics were poor prognostic factors after HR and potent predictors for local recurrence or tumor cell seeding after RFA.

The prognosis of HCC after HR was excellent, if the positive number of tumor markers were within a value of 2. For the RFA-treated group in the Kumamoto cohort, double-positive patients showed equally poor prognosis compared to triple-positive patient. Conversely, in the Wakayama cohort—limited to double-positive patients—the prognoses were similar in patients undergoing HR and RFA. For double positive and triple positive patients, if hepatic function is sufficient then HR should be a first-choice therapy, instead of RFA. If hepatic function is insufficient, RFA in combination with chemoembolization might be recommended, which can improve survival over RFA alone. Prior chemoembolization can reduce arterial blood flow and reduce the heat-sink effect with RFA. Similarly, RFA plus percutaneous alcohol injection or sorafenib administration can enhance the effect of RFA.

Triple positive tumor marker status was an independent poor prognostic factor even after curative HR. In patients with good liver functional reserve, anatomical HR is advocated based on better outcome for HCC patients with MI. Post-operative adjuvant chemoembolization or hepatic arterial chemotherapy for highly malignant HCC might be useful to reduce recurrence in the remnant liver.

In conclusion, preoperative estimation of positive tumor marker number is strongly recommended for HCC patients who undergo local therapy, including HR and RFA.

**Conflict of interest**

The authors have no conflict of interests related to this publication.

**Author contributions**

Conceived the study and drafted the manuscript (TB, SN, HN), performed the analysis and interpretation of data (SN, HN, HQ, TK, KI, HH, YK, KK, DH, YY, AC), revised the paper for important intellectual content (HB, TI). All authors participated in the acquisition of data and approved the final manuscript.

**References**

[1] Cho YK, Kim JK, Kim WT, Chung JW. Hepatic resection versus radiofrequency ablation for very early stage hepatocellular carcinoma: a Markov model analysis. Hepatology 2010;51:1284–1290. doi: 10.1002/hep.23466.

[2] Hasegawa K, Kokudo N, Makuchi M, Izumi N, Ichida T, Kudo M, et al. Comparison of resection and ablation for hepatocellular carcinoma: a cohort study based on a Japanese nationwide survey. J Hepatol 2010;53:724–729. doi: 10.1016/j.jhep.2012.11.009.

[3] Imai K, Beppu T, Chikamoto A, Doi K, Okabe H, Hayashi H, et al. Comparison between hepatic resection and radiofrequency ablation as first-line
treatment for solitary small-sized hepatocellular carcinoma of 3 cm or less. Hepatol Res 2013;43:853–864. doi: 10.1111/hepr.12035.

[4] Toyoda H, Kumada T, Kiyama S, Sone Y, Tanikawa M, Hisanaga Y, et al. Prognostic significance of simultaneous measurement of three tumor markers in patients with hepatocellular carcinoma. Clin Gastroenterol Hepatol 2006;4:111–117.

[5] Tsuchiya Y, Anukulkarnkosul N, Suwangupl P, Lertmahart S, Harivatvong O, Kulvanijaya P, et al. Clinical characteristics and prognosis of hepatocellular carcinoma: analysis based on serum alpha-fetoprotein levels. J Clin Gastroenterol 2000;31:302–308.

[6] Yano Y, Yamashita F, Kuwaki K, Fukumori K, Kato O, Yamamoto H, et al. Highly sensitive AFP-L3% assay is useful for predicting recurrence of hepatocellular carcinoma after curative treatment pre- and postoperatively. Hepatol Res 2011;41:1036–1045. doi: 10.1111/j.1872-034X.2011.00858.x.

[7] Kobayashi M, Ikeda K, Kawai M, Yatsui H, Hosaka T, Sezaki H, et al. High serum des-gamma-carboxy prothrombin level predicts poor prognosis after radiofrequency ablation of hepatocellular carcinoma. Cancer 2009;115:571–580. doi: 10.1002/cncr.24031.

[8] Kobayashi M, Hosaka T, Ikeda K, Seko Y, Kawai M, Yatsui H, et al. Highly sensitive AFP-L3% assay is useful for predicting recurrence of hepatocellular carcinoma after curative treatment pre- and postoperatively. Hepatol Res 2011;41:1036–1045. doi: 10.1111/j.1872-034X.2011.00858.x.

[9] Saito Y, Shimada M, Utsunomiya T, Morine Y, Imura S, Ikemoto T, et al. Prediction of recurrence of hepatocellular carcinoma after curative hepatec- tomy using preoperative Lens culinaris agglutinin-reactive fraction of alpha-fetoprotein. Hepatol Res 2012;42:887–894. doi: 10.1111/j.1872-034X.2012.01004.x.

[10] Masuda T, Beppu T, Horino K, Komori H, Hayashi H, Okabe H, et al. Preoper- ative tumor marker doubling time is a useful predictor of recurrence and prognosis after hepatic resection of hepatocellular carcinoma. J Hepatol 2010;52:490–496. doi: 10.1016/j.jhep.2010.02.010.

[11] Kiyama S, Uchiyama K, Ueno M, Ozawa T, Hayami S, Tani M, et al. Triple positive tumor markers for hepatocellular carcinoma are useful pre- dictors of poor survival. Ann Surg 2011;253:984–991. doi: 10.1097/SLA.0b013e318215016.

[12] Nakagawa S, Beppu T, Okabe K, Sakamoto K, Kuroki H, Mima K, et al. Triple positive tumor markers predict recurrence and survival in early stage he- patocellular carcinoma. Hepatol Res 2014;44:964–974. doi: 10.1111/hepr.12277.

[13] Nakagawa S, Hayashi H, Nitta H, Okabe H, Sakamoto K, Higashi T, et al. Scoring system based on tumor markers and Child-Pugh classification for HCC patients who underwent liver resection. Anticancer Res 2015;35:2157–2163.

[14] Ueno M, Hayami S, Shigekawa Y, Kawai M, Hiroso S, Okada K, et al. Prognostic impact of surgery and radiofrequency ablation on single nodular HCC ≤5 cm: Cohort study based on serum HCC markers. J Hepatol 2015;63:1352–1359. doi: 10.1016/j.jhep.2015.07.013.

[15] Nitta H, Nakagawa S, Ikeda T, Arima K, Higashi T, Taki K, et al. Pre-treatment double- or triple-positive tumor markers are predictive of a poor outcome for patients undergoing radiofrequency ablation for hepatocellular carci- noma. Surg Today 2017;47:375–384. doi: 10.1007/s00595-016-1385-6.

[16] Tsai TJ, Chou CY, Lui WY, Tsay SH, King KL, Loong CC, et al. Clinical signifi- cance of microscopic tumor venous invasion in patients with resectable hepatocellular carcinoma. Surgery 2000;127:603–608. doi: 10.1067/msy. 2000.105498.

[17] Portolan N, Coniglio A, Ghidoni S, Giovannelli M, Benetti A, Tiberio GA, et al. Early and late recurrence after liver resection for hepatocellular carcinoma: prognostic and therapeutic implications. Ann Surg 2006;243:229–235. doi: 10.1097/01.sla.0000197706.21803.a1.

[18] Oishi K, Itamoto T, Amaro H, Fukuda S, Ohdan H, Tashiro H, et al. Clinical- pathologic features of poorly differentiated hepatocellular carcinoma. J Surg Oncol 2007;95:311–316. doi: 10.1002/jso.20661.

[19] Imai K, Beppu T, Nakayama Y, Ishiko T, Horino K, Komori H, et al. Preoper- ative prediction of poorly differentiated components in small-sized hepatocellular carcinoma for safe local ablation therapy. J Surg Oncol 2009;100:121–126. doi: 10.1002/jso.21302.

[20] Choi KK, Kim SH, Choi SB, Lim JH, Choi GH, Choi JS, et al. Portal venous invasion: the single most independent risk factor for immediate postopera- tive recurrence of hepatocellular carcinoma. J Gastroenterol Hepatol 2011; 26:1646–1651. doi: 10.1111/j.1440-1746.2011.06780.x.

[21] Llovet JM, Vilana R, Bru C, Blanc L, Salmeron JM, Boix L, et al. Increased risk of tumor seeding after percutaneous radiofrequency ablation for single hepatocellular carcinoma. Hepatology 2001;33:1124–1129. doi: 10.1053/jhep.2001.24233.

[22] Yu HC, Cheng JS, Lai KH, Lin CP, Lo GH, Lin CK, et al. Factors for early tumor recurrence of single small hepatocellular carcinoma after percuta- neous radiofrequency ablation therapy. World J Gastroenterol 2005;11:1439–1444.

[23] Minami Y, Nishida N, Kudo M. Therapeutic response assessment of AFA for HCC: contrast-enhanced US, CT and MRI. World J Gastroenterol 2014; 20:4160–4166. doi: 10.3748/wjg.v20.i15.4160.

[24] Imamura J, Tateishi R, Shiina S, Goto E, Sato T, Ohki T, et al. Neoplastic seeding after radiofrequency ablation for hepatocellular carcinoma. Am J Gastroenterol 2008;103:3057–3062. doi: 10.1111/j.1572-0241.2008.02153.x.

[25] Liu Z, Gao F, Yang G, Singh S, Lu M, Zhang T, et al. Combination of radio- frequency ablation with transarterial chemoembolization for hepatocellular carcinoma: an up-to-date meta-analysis. Tumour Biol 2014;35:7407–7413. doi: 10.1007/s13277-014-1976-z.

[26] Chen L, Sun J, Yang X. Radiofrequency ablation-combined multimodel therapies for hepatocellular carcinoma: Current status. Cancer Lett 2016; 370:78–84. doi: 10.1016/j.canlet.2015.09.020.

[27] Imamura H, Matsuyama Y, Miyagawa Y, Ishida K, Shimada R, Miyagawa S, et al. Prognostic signification of anatomical resection and des-gamma- carboxy prothrombin in patients with hepatocellular carcinoma. Br J Surg 1999;86:1032–1038. doi: 10.1046/j.1365-2168.1999.01185.x.

[28] Ishii M, Mizuguchi T, Kawamoto M, Meguro M, Ota S, Nishidate T, et al. Combination of radiofrequency ablation with radiofrequency ablation for hepatocellular carcinoma: an up-to-date meta-analysis. Tumour Biol 2014;35:7407–7413. doi: 10.1007/s13277-014-1976-z.

[29] Beppu T, et al: Positive tumor marker number status and HCC. Journal of Clinical and Translational Hepatology 2017 vol. 5 | 165–168